Piper Jaffray Companies reissued their overweight rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research note issued to investors on Thursday. They currently have a $14.71 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $188.00.
A number of other analysts also recently issued reports on the company. B. Riley assumed coverage on Alnylam Pharmaceuticals in a research report on Wednesday. They issued a buy rating and a $240.00 target price on the stock. FBR & Co initiated coverage on Alnylam Pharmaceuticals in a report on Monday, October 30th. They set a buy rating and a $150.00 price target for the company. Goldman Sachs Group, Inc. (The) upgraded Alnylam Pharmaceuticals from a neutral rating to a buy rating and lifted their price target for the stock from $62.00 to $163.00 in a report on Monday, October 2nd. Jefferies Group LLC lifted their price target on Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the stock a buy rating in a report on Tuesday, September 26th. Finally, Chardan Capital reiterated a buy rating and set a $124.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, September 25th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and sixteen have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $109.66.
Alnylam Pharmaceuticals (NASDAQ ALNY) traded down $1.23 during trading hours on Thursday, hitting $132.36. The company had a trading volume of 1,460,580 shares, compared to its average volume of 1,126,231. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.84 and a current ratio of 8.84. Alnylam Pharmaceuticals has a twelve month low of $31.42 and a twelve month high of $147.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). The company had revenue of $15.93 million during the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. Alnylam Pharmaceuticals’s revenue was up 82.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.05) EPS. analysts anticipate that Alnylam Pharmaceuticals will post -5.14 earnings per share for the current year.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 85,316 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Akshay Vaishnaw sold 33,666 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the transaction, the executive vice president now owns 45,201 shares of the company’s stock, valued at $5,490,113.46. The disclosure for this sale can be found here. Over the last quarter, insiders sold 215,797 shares of company stock valued at $25,035,072. 4.30% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in ALNY. QS Investors LLC raised its position in Alnylam Pharmaceuticals by 59.7% during the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 900 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 167 shares in the last quarter. Prudential Financial Inc. acquired a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $215,000. CIBC Asset Management Inc acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $221,000. Finally, Neuberger Berman Group LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $229,000. Institutional investors and hedge funds own 94.39% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
What are top analysts saying about Alnylam Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alnylam Pharmaceuticals Inc. and related companies.